HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VISEN PHARMA-B

45.300

+0.2800.62%

Volume:6.00K

Turnover:272.87K

Market Cap:5.16B

PE:-23.28

High:45.980

Open:45.020

Low:45.020

Close:45.020

52wk High:69.150

52wk Low:39.250

Shares:114.00M

HK Float Shares:114.00M

Volume Ratio:0.63

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.946

ROE:-57.66%

ROA:-29.52%

PB:19.57

PE(LYR):-23.28

PS:1700.64

Loading ...

Overview Company News Filings

Company Profile

Company Name:

VISEN PHARMA-B

Exchange:

SEHK

Establishment Date:

2018

Employees:

58

Office Location:

Building B, Hengtai Lixiang Chuangxin Tower,Suite 3-108, Floor 3,69 Jiuzhang Road,Wuzhong District,Suzhou,Jiangsu Province,China

Website:

http://www.visenpharma.com

Zip Code:

215000

Phone:

- -

Fax:

- -

Introduction:

Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.

Directors

Name

Position

FU Shan

Chairman of the Board,Director,Chairman of the Nomination Committee

LU An Bang

Executive Director,Member of the Remuneration and Assessment Committee

YAO Zhengbin (Bing)

Independent Director,Member of the Nomination Committee,Member of the Audit Committee

CHEN Bing Jun

Independent Director,Member of the Remuneration and Assessment Committee,Chairman of the Audit Committee

Hope Ni

Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee

ZHANG

Independent Director,Member of the Audit Committee

CAO Yi Bo

Director

WU Jian

Advisor

Shareholders

Name

Position

LU An Bang

CEO

CHEN Shi Ting

Corporate Secretary

CHEN Jun

Chief Business Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02561/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"VISEN PHARMA-B","latestPrice":45.3,"timestamp":1757404707997,"preClose":45.02,"halted":0,"volume":6000,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"Not Yet Opened","change":0.28,"latestTime":"09-09 15:58:27","open":45.02,"high":45.98,"low":45.02,"amount":272866,"amplitude":0.021324,"askPrice":45.52,"askSize":200,"bidPrice":45.28,"bidSize":700,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":45.02,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":0.628931,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":0.628931,"shares":113999999,"dividePrice":0,"high":45.98,"amplitude":0.021324,"preClose":45.02,"low":45.02,"week52Low":39.25,"pbRate":"19.57","psRate":"1700.64","week52High":69.15,"institutionHeld":0,"latestPrice":45.3,"committee":0.555556,"eps":-1.946273,"divideRate":0,"volume":6000,"delay":0,"ttmEps":-1.946273,"open":45.02,"prevYearClose":68.8,"prevWeekClose":45.28,"prevMonthClose":45.68,"prevQuarterClose":45.3,"fiveDayClose":44.8,"twentyDayClose":48.9,"sixtyDayClose":53.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746288000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-09-08","current":-23.637534,"percent":0.908257,"low":-30.760225,"twenty":-28.092535,"median":-27.098554,"eighty":-25.818169,"high":-17.514985,"avg":-26.59862,"sd":2.430211,"marketCap":4708478107},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-29","current":-26.119434,"twenty":-28.10544,"median":-27.144467,"eighty":-26.021282,"marketCap":5204179147},{"date":"2025-09-05","current":-23.791598,"twenty":-28.093765,"median":-27.114576,"eighty":-25.835301,"marketCap":4735670561},{"date":"2025-09-08","current":-23.637534,"twenty":-28.092535,"median":-27.098554,"eighty":-25.818169,"marketCap":4708478107}],"updateTime":1757414623454},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1935304080,"yearFounded":2018,"employeeNum":58,"address":"Building B, Hengtai Lixiang Chuangxin Tower,Suite 3-108, Floor 3,69 Jiuzhang Road,Wuzhong District,Suzhou,Jiangsu Province,China","zipCode":"215000"},"stockCompanyDetail":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.0112},{"period":"1month","weight":-0.0208},{"period":"3month","weight":-0.0362},{"period":"6month","weight":-0.3416},{"period":"ytd","weight":-0.3416}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0434},{"period":"3month","weight":0.0645},{"period":"6month","weight":0.1055},{"period":"1year","weight":0.5083},{"period":"ytd","weight":0.293}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.","exchange":"SEHK","name":"VISEN PHARMA-B","nameEN":"VISEN PHARMA-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":{"directors":[{"name":"FU Shan","position":"Chairman of the Board,Director,Chairman of the Nomination Committee"},{"name":"LU An Bang","position":"Executive Director,Member of the Remuneration and Assessment Committee"},{"name":"YAO Zhengbin (Bing)","position":"Independent Director,Member of the Nomination Committee,Member of the Audit Committee"},{"name":"CHEN Bing Jun","position":"Independent Director,Member of the Remuneration and Assessment Committee,Chairman of the Audit Committee"},{"name":"Hope Ni","position":"Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee"},{"name":"ZHANG","position":"Independent Director,Member of the Audit Committee"},{"name":"CAO Yi Bo","position":"Director"},{"name":"WU Jian","position":"Advisor"}],"executives":[{"name":"LU An Bang","position":"CEO"},{"name":"CHEN Shi Ting","position":"Corporate Secretary"},{"name":"CHEN Jun","position":"Chief Business Officer"}]}}}